JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29

Benzinga Newsdesk www.benzinga.com Positive 85.3%

Neg 0% Neu 0% Pos 85.3%

JP Morgan analyst Brian Cheng maintains Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight and raises the price target from $26 to $29.